SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending downwards, with community members debating potential support levels and the impact of a possible rate hike from the Bank of Japan. Some traders are anticipating a bounce, while others believe the price will continue to decline, potentially triggering liquidations and further market corrections. Sentiment seems mixed as participants assess both technical indicators and broader macroeconomic factors.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry ($BB.TSX) is trending as investors analyze the potential impact of upcoming earnings and partnerships, especially regarding QNX technology. Bullish sentiment is fueled by optimism around QNX's expanding role in automotive and IoT, with community members closely watching technical indicators and revenue potential. Discussions also involve institutional investment trends and potential market catalysts.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is trending as traders discuss the potential for a rebound amid fluctuating weather forecasts and debate whether natural gas prices are already reflecting winter demand; the community is actively analyzing technical indicators and storage data, while considering factors like LNG exports and production levels to gauge future price movements.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF ($BTC) is trending as the crypto market experiences volatility, with community members debating potential support levels and future price movements. Some traders are eyeing opportunities in options, while others express concerns about market liquidity and potential pullbacks. Broader discussions include the impact of macro factors like interest rates and potential regulatory developments in the crypto space.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

FRMI is experiencing significant volatility as investors debate its future as an energy provider for data centers, particularly after a canceled funding agreement; the stock saw a sharp decline but is now recovering. Community discussion centers on political connections, potential new tenants (including speculation around big tech partnerships), and the company's ambitious plans in the Texas energy market. Despite some skepticism about its current financials, the stock continues to generate buzz due to its unique position and the growing demand for AI infrastructure.

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Immunome Inc

Immunome ($IMNM) is trending amid discussions surrounding topline results from their Phase 3 RINGSIDE trial for desmoid tumors, expected soon, and a recent analyst upgrade. While some investors express nervousness about the lack of previously discussed progression-free survival (PFS) data, the community is actively debating the potential for a significant stock pop based on trial outcomes. Bullish investors point to high-end salaried job postings as a sign of confidence in the pipeline.

Equinox Gold Corp. is a growth-focused mining company, which engages in the exploration of gold mining properties. It operates through the following segments: Greenstone, Mesquite, Castle Mountain, Los Filos, Aurizona, Fazenda, RDM, Santa Luz, and Corporate. The company was founded by Marc Pais on March 23, 2007, and is headquartered in Vancouver, Canada.

Equinox Gold Corp

Equinox Gold is trending due to the announcement of selling its Brazil operations for over $1 billion, a move aimed at focusing on North American growth and generating significant upfront cash. The community is discussing the potential upside from this strategic shift, especially with the price of gold holding strong, and some are noting large call option purchases signaling bullish sentiment. Some analysts have also raised their price targets, adding to the positive momentum.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as investors digest economic data and speculate on the Fed's next moves, particularly regarding rate cuts and a potential shift in leadership. Community discussions revolve around the impact of these factors on bond yields and the broader market, with some expressing concerns about inflation and the strength of the economic recovery. The ETF's performance is also influenced by global factors like the Bank of Japan's policy and trade dynamics.

Anheuser-Busch InBev SA/NV operates as a holding company, which engages in the manufacture and distribution of alcoholic and non-alcoholic beverages. It operates through the following geographical segments: North America, Middle Americas, South America, EMEA, Asia Pacific, and Global Export and Holding Companies. The company was founded on August 2, 1977 and is headquartered in Leuven, Belgium.

Anheuser-Busch InBev SA/NV - ADR

Anheuser-Busch InBev

Recent acquisitions, potential partnerships with cannabis companies, and digital transformations are driving conversation around $BUD, with some investors seeing it as undervalued. However, debate continues around the company's prior marketing decisions and their impact on market share, as well as broader trends in alcohol consumption and consumer preferences. Some analysts are downgrading the stock, while others are maintaining a positive outlook.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

Bitwise XRP ETF is trending as the community discusses its potential impact and recent performance, including comparisons to other crypto ETFs. Discussions range from technical analysis and market predictions to the broader implications of institutional investment in XRP and its role in bridging traditional finance with cryptocurrency. Some traders are pointing to volume as a key factor for a potential turnaround.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The FDA designation expands Atossa’s investigational therapy into rare pediatric neuromuscular disease.</li><li>The program could become eligible for a Priority Review Voucher upon future approval.</li><li>Preclinical data remains encouraging, with the therapy not limited to exon-specific targeting.</li></ul>Shares of Atossa Therapeutics (ATOS) rose 10% on Thursday after the company said the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to its investigational therapy (Z)-Endoxifen for Duchenne Muscular Dystrophy.<h2 class="st-heading-2">Potential For Priority Review Voucher</h2>The company said the designation expands the program into rare pediatric neuromuscular disease and may qualify Atossa for a Priority Review Voucher (PRV) upon future approval.&nbsp;The Rare Pediatric Disease designation is reserved for serious or life-threatening conditions affecting individuals from birth to 18 years old. Atossa noted that FDA authority to award new vouchers may lapse unless renewed, with pending U.S. legislation seeking to extend the program through 2029.Janet Rea, Senior Vice President of Research and Development, said emerging preclinical data is encouraging and noted that (Z)-Endoxifen does not target specific genetic errors, potentially allowing broader applicability.<h2 class="st-heading-2">Last Week’s FDA Interaction</h2>Last week, Atossa completed a Type C meeting with the FDA to review regulatory strategy for advancing (Z)-Endoxifen across metastatic disease, neoadjuvant treatment and breast cancer risk-reduction settings. The FDA provided feedback on expedited regulatory pathways, clinical development design and endpoint strategy that the company said could support a streamlined registrational approach.CEO Steven Quay said the meeting allowed the company to incorporate FDA input into development planning and could shorten its regulatory timeline. Rea said the clinical program is now supported by data from nearly 800 participants enrolled across multiple trials.<h2 class="st-heading-2">Drug Targets Key Cancer Pathways</h2>(Z)-Endoxifen is a medicine designed to block and break down estrogen receptors, including in tumors that no longer respond to other hormone treatments. It also acts on another cancer-related pathway called protein kinase C beta 1.Atossa is developing an oral version of the drug that passes through the stomach without being changed. This prevents some of the active form from turning into an inactive form and helps keep the drug working as intended.Clinical studies in nearly 800 adults, including both healthy volunteers and people with breast cancer, have shown the drug to be well tolerated at doses up to 360 mg per day, with no maximum tolerated dose identified.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Atossa was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:974/145;" src="https://news.stocktwits-cdn.com/atos_ss_png_38ed63cfce.webp" alt="atos ss.png" width="974" height="145"><figcaption>ATOS sentiment and message volume as of December 11| Source: Stocktwits</figcaption></figure>One bullish user said compliance might still be achievable given Atossa’s current position, though they noted it would depend on the stock staying above $1 or on fresh fund inflows.<stembedurl>https://stocktwits.com/saruribbon/message/638865009</stembedurl>Another user said they were “100% confident we get fda fast track for p3 [phase 3].”&nbsp;<stembedurl>https://stocktwits.com/Mrwwonka/message/638864270</stembedurl><a href="https://stocktwits.com/symbol/ATOS">Atossa’s stock</a> has declined 3.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Atossa Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track

The FDA’s designation broadens Atossa’s development pathway in DMD and could make the program eligible for a Priority Review Voucher.

Equity

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for...

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen Atossa Therapeutics Announces Issuance of...

Ascendiant Capital Markets Forecasts Strong Price Appreciation for Atossa Genetics (NASDAQ:ATOS) Stock

Ascendiant Capital Markets lifted their price objective on Atossa Genetics from $7.75 to $8.00 and gave the company a "buy" rating in a report on Monday...

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across...

Atossa Genetics Inc. (NASDAQ:ATOS) Given Average Rating of "Hold" by Analysts

Shares of Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) have been assigned an average rating of "Hold" from the five analysts that are covering the company, Marketbeat.com reports. Two...

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma Insilico Medicine and...

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation Atossa...

Atossa Genetics (NASDAQ:ATOS) Posts Quarterly Earnings Results, Meets Estimates

Atossa Genetics (NASDAQ:ATOS - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07...

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update PR...

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

ATOS
Atossa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATOS News

ATOSAtossa Therapeutics Inc